Ignite Creation Date:
2024-07-17 @ 11:13 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06469944
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-06-17
Brief Title:
Substudy 06C A Study of Sacituzumab Tirumotecan MK-2870 With Pembrolizumab MK-3475 and Chemotherapy in Participants With First-Line Locally Advanced UnresectableMetastatic Gastroesophageal Adenocarcinoma MK-3475-06CKEYMAKER-U06
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-07-15
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-01-17
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-04-12
Completion Date Type:
ESTIMATED
First Submit Date:
2024-06-17
First Submit QC Date:
None
Study First Post Date:
2024-06-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-18
Last Update Post Date:
2024-06-24
Last Update Post Date Type:
ACTUAL